Educational Activities Archives

Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.

Overdose is the leading cause of accidental injury death in the United States, surpassing motor vehicle crashes, claiming more than 100,000 American lives annually in 2022 and 2023. Promisingly, overdose deaths dropped to 80,341 in 2024. Fentanyl, a synthetic opioid sold as heroin and counterfeit prescription opioids, and commonly contaminating cocaine and methamphetamine, is driving surges in overdose deaths in most communities. This course will introduce tools to combat overdose, which include overdose education and naloxone distribution, compassionate overdose response, drug checking, engagement and treatment, and safety planning.

Substance Use disorders in Older Adults is a growing problem not only in the United States but throughout the developed world. The Baby Boomer generation, born between 1946 and 1964 is turning 58-76 years old this year. This group is presenting with more Substance Use Disorders and need for substance use treatment now. The use of an artificial cut off age of 65 years of age as the definition of elderly or old is somewhat arbitrary and this will be discussed. The module will look at the prevalence, screening and treatment of tobacco, alcohol, opioids, non-medical use of prescription drugs and illicit opioids as well as stimulants and cocaine, marijuana and non-opioid sedative hypnotic agents. A case vignette will drive the CME portion and elucidate the tenants of the module.

According to the Substance Abuse and Mental Health Services Administration, in 2019, only 10% of adults in the U.S with any substance use disorder (SUD) received treatment in part because effective evidence-based treatments for SUDs can be difficult to access in many communities.  CCBHCs help address this issue, delivering easily accessible and effective outpatient behavioral health care and SUD treatment through activities including expanded operating hours, same-day and walk-in appointments, outreach to sidelined populations and moving service delivery beyond clinic walls to reach people in their homes and in the community.

Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.

This session explores the clinical and policy landscape of providing medications for opioid use disorder (MOUD) in jails, prisons, and reentry settings. Dr. Arthur Robin Williams and Dr. Peter Treitler review recent research on the effectiveness of MOUD in reducing overdose and improving post-release treatment engagement. The session highlights key differences among methadone, buprenorphine, and extended-release naltrexone, including regulatory and logistical considerations unique to correctional environments. Learners will examine policy updates, case-based examples, and implementation strategies that support evidence-based treatment access. The session also addresses interdisciplinary collaboration, diversion concerns, and continuity of care across incarceration and reentry.